Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Paradigm Biopharmaceuticals Ltd. announced a change in the director’s interest as Matthew James Fry allowed 1,302,372 options expiring on November 30, 2024, to lapse. Fry continues to hold 1,419,830 fully paid ordinary shares, reflecting a strategic adjustment in his investment with the company. This move could signal a shift in focus or financial strategy for both Fry and Paradigm Biopharmaceuticals.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
